Abstract
This study examines the relationship between 287 pharmaceutical firms’ patent quality and their performance, measured by the profitability ratio and return on assets (ROA) in India. ROA measures the economic efficiency in relation to its overall resource, whereas the profitability ratio measures how much a firm can earn a profit on a rupee of sales. Based on the theoretical model, this study hypothesized that the quality of both product and process innovation positively impacts the firm performance. The quality of patent (innovation) is measured through Revealed Technology Advantage (RTA) and Relative Patent Position (RPP) in the most important technology, i.e. a technology where firms have a maximum patent. RTA measures the technological competencies in one particular technological field compared to other firms. On the other hand, RPP measures the firms leading position in a technological field compared to leader firms in that technology. The results drawn for both quality indicators (RTA and RPP) using quantile regression find significant differences among product and process innovation. Moreover, this study indicates that pharmaceutical firms should enhance their R&D capabilities and the leading position in the most important technology to increase their performance.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Innovation and Technology Management
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
